Camptothecins in cancer therapy
著者
書誌事項
Camptothecins in cancer therapy
(Cancer drug discovery and development)
Humana Press, c2005
- : hard
- : e-ISBN
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographies and index
内容説明・目次
- 巻冊次
-
: hard ISBN 9781588290274
内容説明
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.
目次
Part I: Biochemistry, Pharmacology, and Chemistry
Mechanism of Action of Topoisomerase 1 Poisons
Leroy F. Liu and Shyamal D. Desai
Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage
Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart
Inhibitors of Topoisomerase I Function
Sidney M. Hecht
Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors
Yves G. Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao
Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage
Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti
Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton
Mechanisms of Resistance to Camptothecins
Zeshaan A. Rasheed and Eric H. Rubin
Recent Advances in Camptothecin Drug Design and Delivery Strategies
Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus
Part II: Clinical Perspectives
Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development
Chris H. Takimoto
Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
Hilary Hewes, Judith A. Smith, and Claire Verschraegen
Irinotecan: Current Clinical Status and Pharmacological Aspects
Laurent P. Rivory
Clinical Experience With Topotecan
Aimee K. Bence and Val R. Adams
The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms
Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer
Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog
Eric K. Rowinsky
Camptothecins in the Treatment of Primary Brain Tumors
Clinton F. Stewart,Markos Leggas, and Henry S. Friedman
Camptothecins in the Treatment of Lung Cancer
Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler
Use of Camptothecins in the Treatment of Leukemia and Related Disorders
Benjamin M. F. Mow and Scott H. Kaufmann
Index
- 巻冊次
-
: e-ISBN ISBN 9781592598663
内容説明
The text provides an up to the minute summary of what is known today about the biochemistry and pharmacology of the camptothecins. The chapter that covers this subject includes a discussion of the mechanism of action of topoisomerase I, and a review of the means by which camptothecins poison this enzyme. The use of animal models in defining the anticancer potential of camptothecins and a discussion of camptothecin resistance is included. Part two of the text is devoted to a review of new analogue development as well as drug delivery issues that are aimed at optimizing the anticancer activities of camptothecins. In the last section of the book the clinical perspective is presented. The authors have included current summaries on each of the members of the camptothecin families that have been studied in the clinic. Along with these reviews discussions of the potential use of camptothecins in a variety of different cancers has been included.
目次
- Part I. Biochemistry, Pharmacology, and Chemistry
- Mechanism of Action of Topoisomerase I Poisons
- Leroy F. Liu and Shyamal D. Desai
- Crystallographic Insight into the Mechanism of Drug-Induced Topoisomerase I DNA damage
- Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart
- Inhibitors of Topoisomerase I Function
- Sidney M. Hecht
- Cytotoxic Mechanisms of the Topoisomerase I Inhibitors
- Yves Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao
- Biochemical and Genetic Analyses of DNA Topoisomerase I-Mediated DNA Damage
- Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti
- Preclinical Models for Evaluating Topoisomerase-I Targeted Drugs
- Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter Houghton
- Mechanisms of Resistance to Camptothecins
- Zeshaan A. Rasheed and Eric H. Rubin
- Recent Advances in Camptothecin Drug Design and Delivery Strategies
- Thomas G Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus
- Part II. Clinical Perspectives
- Clinical Experience with 9-Aminocamptothecin: Lessons for New Drug Development
- Chris H. Takimoto
- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
- Hilary Hewes, Judith A. Smith, and Claire Verschraegen
- Irinotecan: Current Clinical Status and Pharmacological Aspects
- Laurent P. Rivory
- Clinical Experience with Topotecan
- Aimee K. Bence and Val R. Adams
- The Clinical Development of Lurtotecan: Experience with Water-Soluble and Liposomal Forms
- Keith T. Flatherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer
- Preclinical and Clinical Development of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin Analog
- Eric K. Rowinsky
- Camptothecins in the Treatment of Primary Brain Tumors
- Clinton F. Stewart, Markos Leggas, and Henry S. Friedman
- Camptothecins in the Treatment of Lung Cancer
- Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler
- 'Use of Camptothecins in the Treatment of Leukemia and Related Disorders
- Bejamin M. F. Mow and Scott H. Kaufmann
「Nielsen BookData」 より